Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q2 2026 · 10-Q
Revenue$250.00K$250.00Kno prior Q2 2025 on file Net Income$388.15K$388.15K+39.7% vs Q2 2025 EPS Diluted$0.00$0.00— vs Q2 2025 Operating Income-$843,565N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-337.4%
Net margin155.3%
ended Jun 30, 2026 · filed Aug 13, 2026 · 44 d after period end